FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma
FaR-RMS is an over-arching study for children and adults with newly diagnosed and relapsed rhabdomyosarcoma (RMS)
Trial Details
- NCT ID
- NCT04625907
- Phase
- PHASE1 / PHASE2
- Sponsor
- University of Birmingham
- Status
- RECRUITING
- Cancer Type
- Rhabdomyosarcoma Sarcoma
- Interventions
- Irinotecan
- Actinomycin D
- Doxorubicin
- Ifosfamide
- Vincristine
- Vinorelbine
- Locations (sample)
- Brisbane, Australia|-27.46794,153.02809
- Camperdown, Australia|-33.88965,151.17642
- Clayton, Australia|-37.91667,145.11667
- Melbourne, Australia|-37.814,144.96332
- New Lambton Heights, Australia|-32.92466,151.69364
Key Eligibility Criteria
- Histologically confirmed diagnosis of RMS (except pleomorphic RMS)
- Written informed consent from the patient and/or the parent/legal guardian
- Phase 1b Dose Finding - IRIVA Inclusion
- Entered in to the FaR-RMS study at diagnosis
For full eligibility, visit ClinicalTrials.gov.